Medikit (7749) Fundamentals 2026 — P/E 13.6x, Revenue Analysis | SniperIQ
Medikit (7749) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥40.6B, trading at ¥2805.00 on the JPX. This SniperIQ fundamentals page covers Medikit's valuation (P/E 13.6x, P/B 0.9x), profitability (net margin 12.6%), revenue (¥23.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Medikit's market cap?
Medikit (7749) has a market capitalization of approximately ¥40.6B, trading at ¥2805.00 on the JPX. Market cap moves with the live share price.
What is Medikit's P/E ratio?
Medikit's trailing twelve-month P/E ratio is 13.6x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Medikit?
Medikit runs a net profit margin of 12.6%, a gross margin of 35.5%, and an operating margin of 18.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Medikit generate?
Medikit reported revenue of ¥23.8B for fiscal year 2025, with net income of ¥3.0B and earnings per share (EPS) of 206.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Medikit pay a dividend?
Medikit offers a trailing dividend yield of about 3.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Medikit financially healthy?
Medikit carries a debt-to-equity ratio of 0.00x and a current ratio of 6.25x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Medikit a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medikit (7749) the key facts are: market cap ¥40.6B, P/E 13.6x, revenue ¥23.8B, 52-week range 2503-3095. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Medikit's full fundamentals live
Get Medikit's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.